Original Research

Mequinol 2%/Tretinoin 0.01% Solution: An Effective and Safe Alternative to Hydroquinone 3% in the Treatment of Solar Lentigines

A new topical solution containing 4-hydroxyanisole (mequinol) 2%/tretinoin 0.01% (Solagé®) was compared with its active components, its vehicle, and hydroquinone (HQ) 3% in the treatment of solar lentigines. In a randomized, parallel-group, double-masked study, 216 subjects applied the treatments twice daily for 16 weeks and were followed up for a further 24 weeks. A significantly higher proportion (P


 

Recommended Reading

Skin Reaction Following Immunization With Smallpox Vaccine: A Personal Perspective
MDedge Dermatology
Actinic Keratoses—Surgical and Physical Therapeutic Modalities
MDedge Dermatology
Treatment of Molluscum Contagiosum With the Pulsed Dye Laser Over a 28-Month Period
MDedge Dermatology
The Effects of an Estrogen and Glycolic Acid Cream on the Facial Skin of Postmenopausal Women: A Randomized Histologic Study
MDedge Dermatology
Prevention of Cross-Contamination When Using Microdermabrasion Equipment
MDedge Dermatology
Cutaneous Laser Surgery in Darker Skin Phototypes
MDedge Dermatology
Cutaneous Sarcoidosis at Sites of Previous Laser Surgery
MDedge Dermatology
Dermatology Research Within the Department of Defense
MDedge Dermatology
Over-the-Counter Topical Skin Products—A Common Component of Skin Disease Management
MDedge Dermatology
Safety and Efficacy of Combined Use of 4-Hydroxyanisole (mequinol) 2%/Tretinoin 0.01% Solution and Sunscreen in Solar Lentigines
MDedge Dermatology